Theranostics is a new field of medicine that combines imaging and molecular radiotherapy. Imaging, generally positron emission tomography (PET), is used to identify the tumor, followed by a radiopharmaceutical – a radioactive drug that, like the PET agent that identified it, specifically targets cancer while leaving most healthy tissues alone. Unlike external beam radiotherapy, molecular radiotherapy carries the radioactivity in the form of particles that are emitted from the radiopharmaceutical.
Our approach
M Health Fairview University of Minnesota Medical Center’s dedicated, five-bed radiotheranostics unit is the first of its kind in Minneapolis-St. Paul offering both diagnostic and treatment options. Additionally, the center has been named a Radiopharmaceutical Therapy Center of Excellence by the Society for Nuclear Medicine and Molecular Imaging (SNMMI).
Radiotheranostics is considered the most clinically advanced application of targeted therapy, and uniquely offers patients an advanced therapy option with improved outcomes.
M Health Fairview radiotheranostics’ team of oncologists and nuclear medicine radiologists offers treatment for patients with the following diagnoses:
- I-131 for thyroid cancer.
- Radium 223 Xofigo® for metastatic prostate cancer.
- Lu-177 Lutathera® for neuroendocrine tumors.
- Y-90 microspheres for treating colorectal cancer that has metastasized to the liver.
- 131-I MIBG for pediatric neuroblastoma, as well as for neuroendocrine and paraganglioma tumors.
- Lu-177 PSMA treatment for castrate resistant prostate cancer.
- Cerianna™ PET imaging for HER2-positive breast cancer.
Accreditations & Certifications
Image
